Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

NEW ISSUE: Biogroup/CAB E350m 3.375% sr sec add-on in the market

HYC European Market: Deal Flow - General

CAB Selas (Biogroup) (BIOGRP) EUR350m 144A/Reg S add-on to its 3.375% sr sec notes due 02/01/28 (6.25y). NC2.25 (02/01/24) (MWC B+50bp), then at 101.688, 100.844, 100. Equity claw: 2.25y 40% at 103.375. Special call: 10% per year the 1st 2.25 years at 103. Existing B2/B/B+. Via BNP/Natixis (B&D) jt glocos and jt physical books/JPM jt glocos/Citi/CA/GS/HSBC/MS jt books. No reg rights. List ISE. NY Law. Reg S ISIN: XS2294186965. Immediately fungible, subject to issue price. Otherwise a mirror offering, with the EUR800m issue priced 01/28/2021.

IPT: 98.00-98.50.

Investor call at 10:30am UKT today. 1x1s virtual meetings today-tomorrow. UOP: finance the acquisition of 100% of Medilys Shares originally financed by cash and fund the acquisition of 89% of LLR Belgique Shares, repay drawings under the Existing Revolver, refinance certain other net debt incurred in the context of the Medilys Acquisition and the LLR Belgique Acquisition, fund cash on balance sheet for GCP. Biz: Leading private medical laboratory testing business in France and Belgium.

We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.